Cancer Institute

  • Radhika Pochampally

    pochampally_radhika.jpgAssociate Professor, Department of Biochemistry
    Cancer Genetics Program
    PhD, Microbiology/Cancer biology, 2000, Louisiana State University Health Sciences Center, New Orleans.
    Postdoc, 2001-04, Tulane University Health Science Center, New Orleans, LA

    Contact information
    2500 N State St., Room R761
    Jackson, MS 39216
    Phone: (601) 815-6832
    E-mail: rpochampally@umc.edu

    Research interests

    • Role of mesenchymal stromal cells in stroma of breast and bone cancers
    • Development of affinity tagged liposomal nanoparticles for cancer therapy

    Research synopsis

    Multipotential Mesenchymal Stromal cells (MSCs) hold great potential for treating human degenerative diseases and injuries. Recent, studies regarding the biology of breast cancer stroma indicate that mesenchymal stem cells (MSCs) provide the supportive stroma for solid tumors. The general focus of research in my laboratory is to understand the stromal supportive properties of Mesenchymal Stem Cells (MSCs) from bone marrow and their therapeutic potential. Projects to understand the therapeutic potential of MSCs include (a) epigenetic regulation of MSCs under stress that mimic microenvironment in solid tumors (b) role of microRNA regulation in survival and differentiation of MSCs (c) post translational regulation using autophagic pathway in the survival of MSCs in solid tumor stroma.

    A second ongoing project aims to understand the role of MSCs in the osteosarcoma genesis and develop targeted nanotechnology based therapeutics. The projects involve (a) Identification of Osteosarcoma tumor initiating cells and (b) develop affinity tagged therapeutic options using targeted curcumin nanoparticles to Osteosarcoma cancer cells. 

    Selected publications

    • Extracellular Vesicles: Evolving Factors in Stem Cell Biology. Nawaz M, Fatima F, Vallabhaneni KC, Penfornis P, Valadi H, Ekström K, Kholia S, Whitt JD, Fernandes JD, Pochampally R, Squire JA, Camussi G. Stem Cells Int. 2016;2016:1073140. doi: 10.1155/2016/1073140. Epub 2015 Nov 16.
    • The current landscape of the mesenchymal stromal cell secretome: A new paradigm for cell-free regeneration. Konala VB, Mamidi MK, Bhonde R, Das AK, Pochampally R, Pal R. Cytotherapy. 2016 Jan;18(1):13-24. doi: 10.1016/j.jcyt.2015.10.008. Epub 2015 Nov 26.
    • Induced pluripotent stem cell-derived mesenchymal stem cells: A leap toward personalized therapies. Whitt J, Vallabhaneni KC, Penfornis P, Pochampally R. Curr Stem Cell Res Ther. 2016;11(2):141-8.
    • Regulation of nucleotide metabolism by mutant p53 contributes to its gain-of-function activities. Kollareddy M, Dimitrova E, Vallabhaneni KC, Chan A, Le T, Chauhan KM, Carrero ZI, Ramakrishnan G, Watabe K, Haupt Y, Haupt S, Pochampally R, Boss GR, Romero DG, Radu CG, Martinez LA. Nat Commun. 2015 Jun 12;6:7389. doi: 10.1038/ncomms8389.
    • Extracellular vesicles from bone marrow mesenchymal stem/stromal cells transport tumor regulatory microRNA, proteins, and metabolites. Vallabhaneni KC, Penfornis P, Dhule S, Guillonneau F, Adams KV, Mo YY, Xu R, Liu Y, Watabe K, Vemuri MC, Pochampally R.,  Oncotarget. 2015 Mar 10;6(7):4953-67.
    • Roles of the cyclooxygenase 2 matrix metalloproteinase 1 pathway in brain metastasis of breast cancer.Wu K, Fukuda K, Xing F, Zhang Y, Sharma S, Liu Y, Chan MD, Zhou X, Qasem SA, Pochampally R, Mo YY, Watabe K.,  J Biol Chem. 2015 Apr 10;290(15):9842-54. doi: 10.1074/jbc.M114.602185. Epub 2015 Feb 17.
    • Extracellular vesicles as carriers of microRNA, proteins and lipids in tumor microenvironment,  Penfornis P, Vallabhaneni KC, Whitt J, Pochampally R.,  Int J Cancer. 2015 Jan 5. doi: 10.1002/ijc.29417.
    • Extracellular vesicles from bone marrow mesenchymal stem/stromal cells transport tumor regulatory microRNA, proteins, and metabolites. Vallabhaneni KC, Penfornis P, Dhule S, Guillonneau F, Adams KV, Mo YY, Xu R, Liu Y, Watabe K, Vemuri MC, Pochampally R. Oncotarget. 2014 Dec 31. [Epub ahead of print]
    • Acidosis promotes invasiveness of breast cancer cells through ROS-AKT-NF-κB pathway. Gupta SC, Singh R, Pochampally R, Watabe K, Mo YY. Oncotarget. 2014 Dec 15;5(23):12070-82.